Filing Details
- Accession Number:
- 0001209191-15-054001
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2015-06-16 20:08:11
- Reporting Period:
- 2015-06-15
- Filing Date:
- 2015-06-16
- Accepted Time:
- 2015-06-16 20:08:11
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1604464 | Atara Biotherapeutics Inc. | ATRA | Biological Products, (No Disgnostic Substances) (2836) | 460920988 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1612095 | Christopher Haqq | 701 Gateway Boulevard Suite 200 South San Francisco CA 94080 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2015-06-15 | 300 | $44.56 | 261,365 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2015-06-15 | 6,100 | $46.34 | 255,265 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2015-06-15 | 1,100 | $47.34 | 254,165 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 20,000 | Indirect | See footnote |
Footnotes
- Transaction pursuant to Rule 10b5-1 Plan adopted March 11, 2015.
- The price in Column 4 is a weighted average sale price. The prices actually received ranged from $46.02 to $46.86. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- The price in Column 4 is a weighted average sale price. The prices actually received ranged from $47.06 to $48.04. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- The shares are held by the Chris Haqq 2014 GRAT, of which the Reporting Person is trustee.
Billionaire Hedge Funds
